Thyroid gland disorder

This study compared a liquid form of thyroid medication (Tirosint-SOL) to crushed tablets in 34 infants with congenital hypothyroidism. The goal was to see which form helps maintain normal thyroid hormone levels more easily. However, the study was stopped early, so firm conclusio…

This early-phase trial tested combinations of the drugs bevacizumab and temsirolimus, sometimes with valproic acid or cetuximab, in 154 people with advanced cancers or certain non-cancerous but progressive diseases. The main goal was to find safe doses and look for any signs that…

This phase 1 study tested the cancer drug pazopanib in 18 frail elderly patients (aged 75+) with metastatic cancers like kidney, lung, or breast cancer. The goal was to find the highest safe dose by starting at 400 mg daily and increasing if tolerated. The study was terminated ea…

This early-phase trial tested a new drug called nanrilkefusp alfa, which helps activate immune cells, both alone and combined with the immunotherapy pembrolizumab. It included 115 people with various advanced solid tumors that had stopped responding to standard treatments. The st…

This phase 2 trial tested whether the immunotherapy drug pembrolizumab, given after radiation therapy, could help control anaplastic thyroid cancer that is still in the neck. Only 6 patients were enrolled before the study was stopped early. The goal was to see how long patients l…

This early-phase study tested a treatment using donated natural killer (NK) cells from cord blood, combined with chemotherapy, for children and young adults with solid tumors that returned or didn't respond to standard care. The goal was to find the safest dose and check for side…

This phase II trial tested two immunotherapy drugs, durvalumab and tremelimumab, in 79 patients with advanced thyroid cancer that had progressed despite treatment. The goal was to see if the combination could slow or stop cancer growth. The study was terminated early, so the full…

This phase 2 trial tested the drug tovorafenib (DAY101) in 23 people aged 12 and older with recurrent or progressive solid tumors that have specific genetic changes in the MAPK pathway. The goal was to see how many patients' tumors shrank or disappeared. The study was terminated …

This early study tested an experimental oral drug called IK-595 in people with advanced solid tumors that have specific RAS or RAF gene mutations. The goal was to check safety, dosing, and early signs of tumor shrinkage. The study was terminated before completion, so full results…

This study tested a new type of PET scan (called 68Ga-MY6349) that targets a protein called Trop-2 on cancer cells. It was used in 149 adults with thyroid cancer to see if it could find cancer that had come back or spread. The results were compared to the standard FDG-PET scan to…

This early study tested a hand-held imaging device to help surgeons identify parathyroid glands during thyroid surgery. The parathyroid glands are small and hard to see, and if accidentally removed or damaged, can cause low calcium levels and other complications. The device uses …

This study tested a new 3D ultrasound technique called acoustic angiography to improve imaging of breast and thyroid tumors. Researchers planned to enroll 45 people, including healthy volunteers and patients scheduled for biopsy. The study was stopped early due to funding problem…

This small pilot study tested whether metformin, a common diabetes drug, could reduce side effects like dry mouth and taste changes from radioactive iodine treatment in people with thyroid cancer. Only 13 people took part, and the study was stopped early. The goal was to see if m…

This study investigated whether polyomaviruses (a type of common virus) are found more often in people with autoimmune thyroiditis or goiters. Researchers compared virus presence in blood, urine, and thyroid tissue from 49 patients undergoing thyroid surgery. The goal was to see …

This study looked for new genes that might increase the risk of developing differentiated thyroid cancer. Researchers planned to analyze the complete DNA of people with thyroid cancer and their family members. The study was stopped early and involved 34 participants.